On August 10, 2026, the status of clinical trial NCT05502341 was updated to active, not recruiting. The study is titled "Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen." This trial is registered as a Phase 2/Phase 3 study.
The trial involves people with HIV-1 who are described as successfully treated with a complicated regimen, comparing outcomes on bictegravir/lenacapavir against their current therapy. Enfuvirtide is associated with this trial context as part of the complicated regimen category referenced in the study population.
The current status, active not recruiting, indicates that participant enrollment is not ongoing at this time. No results or outcome data have been reported as part of this update. This brief reflects only the status and phase information provided for this registered study.
Enfuvirtide remains classified as an unapproved research compound in the context of this report. For readers seeking more background, further context on enfuvirtide is available on its compound overview page.